Prof David Granville
Dr. Granville is a Professor in Pathology and Laboratory Medicine at the University of British Columbia (UBC), Vancouver, Canada. He is also a Principal Investigator at the International Collaboration On Repair Discoveries (ICORD) Centre and Associate Director of the BC Professional Firefighters’ Burn and Wound Healing Group. His early work at QLT (Vancouver, BC) supported the development and FDA approval of Visudyne®, the first treatment for age-related macular degeneration, the leading cause of blindness in the elderly. In 2001, Dr. Granville relocated to the Scripps Research Institute (La Jolla, CA), where his research identified a novel therapeutic approach for attenuating ischemia and reperfusion injury that led to the formation of Radical Therapeutix Inc (San Diego, CA). In 2003 he was recruited back to UBC and in 2014 was inducted as a Scholar of the Royal Society of Canada. His research is presently focused on the role of immune-secreted proteases in autoimmune and/or chronic inflammatory disorders of the skin and blood vessels. He is currently taking this research to the next level and translating these discoveries into the development and commercialization of novel, first-in-class therapeutics.